{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:11:08Z","timestamp":1785222668736,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nmd.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:47:12Z","timestamp":1685598432000},"page":"619-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychopharmaceutical treatment for neurobehavioral problems in Duchenne muscular dystrophy: a descriptive study using real-world data"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-486X","authenticated-orcid":false,"given":"Pien M.M.","family":"Weerkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Geuens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeroen","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G.M.","family":"Hendriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Klinkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2023.05.011_bib0001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2023.05.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2023.05.011_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0004","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073807309775","article-title":"Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive\u2013compulsive disorder","volume":"23","author":"Hendriksen","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0005","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s10072-018-3341-2","article-title":"Autism spectrum disorders are prevalent among patients with dystrophinopathies","volume":"39","author":"Fujino","year":"2018","journal-title":"Neurolog Sci"},{"key":"10.1016\/j.nmd.2023.05.011_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133214","article-title":"Early neurodevelopmental findings predict school age cognitive abilities in duchenne muscular dystrophy: a longitudinal study","volume":"10","author":"Chieffo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2023.05.011_bib0007","first-page":"497","article-title":"Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients","volume":"43","author":"Cotton","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0008","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.ejhg.5200488","article-title":"Severe cognitive impairment in DMD: obvious clinical indication for Dp71 isoform point mutation screening","volume":"8","author":"Moizard","year":"2000","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2023.05.011_bib0009","article-title":"Dystrophin gene mutation location and the risk of cognitive impairment in duchenne muscular dystrophy","volume":"5","author":"Nogales-Gadea","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2023.05.011_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0011","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nmd.2016.08.003","article-title":"Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: a case report","volume":"26","author":"Hendriksen","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.05.011_bib0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejpn.2018.09.005","article-title":"Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder","volume":"23","author":"Lionarons","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0013","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.26803","article-title":"Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy","volume":"61","author":"Darmahkasih","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.05.011_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12020176","article-title":"Psychopharmacological treatments for mental disorders in patients with neuromuscular diseases: a scoping review","volume":"12","author":"Brusa","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.nmd.2023.05.011_bib0015","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.2169\/internalmedicine.7248-21","article-title":"Duchenne muscular dystrophy successfully treated with aripiprazole in a patient with autism spectrum disorder symptoms including irritability","volume":"60","author":"Noda","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.nmd.2023.05.011_bib0016","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1056\/NEJMsa1413512","article-title":"Trends in mental health care among children and adolescents","volume":"372","author":"Olfson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.05.011_bib0017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/cap.2013.0073","article-title":"Psychotropic medication characteristics for special education students with emotional and\/or behavioral disorders","volume":"24","author":"Mattison","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0018","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1016\/j.ridd.2013.06.009","article-title":"Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability","volume":"34","author":"Scheifes","year":"2013","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.nmd.2023.05.011_bib0019","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jpeds.2012.03.020","article-title":"Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation","volume":"161","author":"Pane","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2023.05.011_bib0021","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/0883073815570154","article-title":"Cognitive and neurobehavioral profile in boys with duchenne muscular dystrophy","volume":"30","author":"Banihani","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3233\/JND-210776","article-title":"Comparing deflazacort and prednisone in duchenne muscular dystrophy","volume":"9","author":"Biggar","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2023.05.011_bib0023","article-title":"Prednisone and deflazacort in duchenne muscular dystrophy: do they play a different role in child behavior and perceived quality of life?","volume":"8","author":"Sienko","year":"2016","journal-title":"PLOS Curr"},{"key":"10.1016\/j.nmd.2023.05.011_bib0024","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1007\/s00787-004-1002-x","article-title":"European clinical guidelines for hyperkinetic disorder\u2013first upgrade","volume":"13","author":"Taylor","year":"2004","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0026","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00787-017-0986-y","article-title":"Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit\/hyperactivity disorder","volume":"26","author":"Coghill","year":"2017","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0027","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00787-009-0054-3","article-title":"Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis","volume":"19","author":"Faraone","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","article-title":"Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine","volume":"31","author":"Hennissen","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.nmd.2023.05.011_bib0029","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0883073817701368","article-title":"Secondary conditions among males with duchenne or becker muscular dystrophy","volume":"32","author":"Latimer","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-4006","article-title":"Implementation of duchenne muscular dystrophy care considerations","volume":"142","author":"Andrews","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.nmd.2023.05.011_bib0031","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejpn.2015.04.005","article-title":"Pain in adolescents with spinal muscular atrophy and duchenne and becker muscular dystrophy","volume":"19","author":"Lager","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2023.05.011_bib0032","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.neubiorev.2020.09.031","article-title":"Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis","volume":"120","author":"Carucci","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.nmd.2023.05.011_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15081789","article-title":"The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): systematic review, meta-analysis, and meta-regression","volume":"15","author":"Liang","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.nmd.2023.05.011_bib0034","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/0706743716659276","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. special populations: youth, women, and the elderly","volume":"61","author":"MacQueen","year":"2016","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0035","series-title":"Handbook of psychiatric drug therapy","author":"Rosenbaum","year":"2010"},{"key":"10.1016\/j.nmd.2023.05.011_bib0036","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","article-title":"Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder","volume":"173","author":"Jakubovski","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0037","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/NDT.S151802","article-title":"Risperidone for children and adolescents with autism spectrum disorder: a systematic review","volume":"14","author":"Maneeton","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.nmd.2023.05.011_bib0038","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.2169\/internalmedicine.7248-21","article-title":"Duchenne muscular dystrophy successfully treated with aripiprazole in a patient with autism spectrum disorder symptoms including irritability","volume":"60","author":"Noda","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.nmd.2023.05.011_bib0039","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-244X-11-83","article-title":"The clinical global impression scale and the influence of patient or staff perspective on outcome","volume":"11","author":"Forkmann","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.nmd.2023.05.011_bib0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1037\/0096-1523.1.3.288","article-title":"Hindsight is not equal to foresight: the effect of outcome knowledge on judgment under uncertainty","volume":"1","author":"Fischhoff","year":"1975","journal-title":"J Exp Psychol Hum Percept Perform"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:14:01Z","timestamp":1760775241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0960896623001487"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.05.011","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychopharmaceutical treatment for neurobehavioral problems in Duchenne muscular dystrophy: a descriptive study using real-world data","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}